Transient receptor potential vanilloid 1 (TRPV1) is a nociceptive cation channel that is activated by heat, protons and chemical ligands such as capsaicin. We investigated the roles of the capsaicin receptor, TRPV1, in controlling the energy metabolism of the whole body. It has been reported that the activation of TRPV1 by its agonists enhances energy metabolism. In this study, we used a respiratory gas analysis system to examine whether the inhibition of TRPV1 changes energy metabolism in mice. In addition, we examined the contributions of different modes of TRPV1 activation (heat, protons and capsaicin) to determine the influence of 3 different TRPV1 antagonists on energy metabolism. Here, we showed that intragastric administration of AMG517, a nonselective antagonist of TRPV1 (for heat, protons and capsaicin), enhanced energy metabolism as much as did intraperitoneal administration. On the other hand, intraperitoneal administration of AMG9810, a nonselective antagonist like AMG517, enhanced energy expenditure more than intragastric administration. However, the administration of JYL1421, a TRPV1 antagonist that very strongly inhibits TRPV1 activated by capsaicin, did not change energy metabolism. Taken together, these results suggest that the type of TRPV1 antagonists and the routes of its administration have different effects on energy metabolism in a normal body. Surprisingly, co-administration of JYL1421 and capsaicin significantly enhanced the energy metabolism more than administration of capsaicin alone. These results support the possibility that an unconventional mechanism is responsible for the increase in energy metabolism that occurs via TRPV1 inhibition.
MATERIALS AND METHODS
Animals. C57BL/6J mice (5-to 6-wks-old; Charles River Laboratories Japan, Inc., Yokohama, Japan) were used. The mice were housed in a vivarium maintained at 23 ± 2°C under a 12 : 12-h light-dark cycle (lights on 0700-1900 h) with free access to a commercial standard laboratory chow (MF; Oriental Yeast Co. Ltd., Tokyo) and drinking water. All experimental protocols were approved by the Guide for Animal Experiments issued by Kyushu University, the Law Concerning the Human Care and Control of Animals (Law No. 105; October 1, 1973) , and the Japanese Government Notification on the Feeding and Safekeeping of Animals (Notification No. 6; March 27, 1980).
Chemicals. AMG517 was purchased from AdooQ
BioScience (Irvine, CA). AMG9810 was obtained from Alomone Labs (Jerusalem, Israel). JYL1421 was purchased from Aobious, Inc. (Gloucester, MA). Other chemical compounds were purchased from Sigma-Aldrich (St. Louis, MO). For single administration, AMG517 was diluted in saline containing 5% ethanol and 5% Tween 80, AMG9810 was diluted in dimethyl sulfoxide containing 14% saline, and JYL1421 was diluted in saline containing 10% ethanol and 5% Tween 80. These solutions were administered at 100 μL/20 g body weight in mice. For co-administration, capsaicin was diluted in saline containing 13% ethanol and 10% Tween 80 and JYL1421 was diluted in saline containing 10% ethanol and 5% Tween 80. These solutions were administered respectively at 50 μL/20 g mouse body weight. The total volume of administration was 100 μL/20 g body weight. The concentrations of TRPV1 antagonists and vehicle compositions were determined by previous studies (1, 8, 9, 18) . We used the same concentrations and vehicles as reference publications.
Respiratory gas analysis. The mice were kept individually in acrylic chambers (width 120 × height 150 × depth 240 mm) for 3 h before the administration to acclimate them to the experimental environment. The mice were prohibited access to food 3 h before the administration. The mice had free access to water during the period in the acrylic chamber. The body weights of the mice were not statistically and EM, and that TRPV1 activation prevents dietinduced obesity (21, 29, 42) . Thus, it is fairly clear that the activation of TRPV1 by TRPV1 agonists enhances thermogenesis and EM. However, there is some confusing evidence regarding TRPV1 antagonists. Because TRPV1 is a pain receptor, TRPV1 antagonists have been examined for their use as analgesic agents (36) . However, many antagonists of TRPV1 have the side effect of inducing hyperthermia in rodents, monkeys, dogs and humans (8-10, 12, 24, 35 ). The precise mechanisms underlying the hyperthermic effect have not been clarified, but one possible reason is the induction of thermogenesis in brown adipose tissue (1) . On the other hand, capsinoids, which are TRPV1 agonists, also increase thermogenesis in brown adipose tissue (19, 27, 31) . Thus, we hypothesized that both TRPV1 antagonists and agonists enhance EM via TRPV1. Verifying this hypothesis must be a key to elucidating the novel roles played by TRPV1 in controlling the EM of the whole body.
In this study, we used 3 different types of TRPV1 antagonist, namely AMG517, AMG9810 and JYL1421 (6) . TRPV1 antagonists can differentially block 3 classes of stimuli (heat, protons and chemical ligands such as capsaicin). AMG517 and AMG9810 are nonselective TRPV1 antagonists that inhibit TRPV1 activated by all stimuli (heat, protons and capsaicin). JYL1421 is a selective TRPV1 antagonist that blocks the class of capsaicin stimulus only (6, 8, 9) . We used these antagonists to reveal whether the inhibition of different functions of TRPV1 affects EM in mice as determined by respiratory gas analysis.
In the present study, we found that intragastric (IG) or intraperitoneal (IP) administration of AMG517 and AMG9810 increased oxygen consumption (VO 2 ) and carbohydrate oxidation (CHO) in mice. Furthermore, IG and IP administration of AMG517 enhanced EM whereas IP administration of AMG9810 enhanced VO 2 and fat oxidation more than did IG administration. However, neither IG nor IP administration of JYL1421 changed VO 2 and CHO under normal conditions. Interestingly, in the case of IG co-administration of JYL1421 and capsaicin, CHO was increased more than IG administration of capsaicin alone. These results suggest that the type of TRPV1 antagonists and their routes of administration have different effects on EM. Moreover, the inhibition of TRPV1 activated by protons, body temperature (because of the decrease of temperature threshold by protons and other endogenous TRPV1 modulators) or capsaicin (exogenous administration) the AMG517 administrations elicited a change in the average respiratory quotient (Fig. 1) .
Administration of AMG9810, a nonselective TRPV1 antagonist, also increased EM
In addition to AMG517, IG administration of AMG9810 enhanced CHO, although VO 2 and fat oxidation were not changed ( Fig. 2A and B) . Still, IP administration of AMG9810 significantly increased VO 2 , fat oxidation, and CHO at a 50 mg/kg dose (Fig. 2D ). These enhancements occurred in a dose-dependent manner ( Fig. 2C and D) . These results suggest that the administration of AMG9810, a nonselective antagonist of TRPV1 that can inhibit all known classes of stimuli, increased EM as well as AMG517. Furthermore, AMG9810 caused different changes in EM in different routes of administration. None of the AMG9810 administrations elicited a change in the average respiratory quotient (Fig. 2) .
Administration of JYL1421, which blocks TRPV1 activated by capsaicin only, did not change EM
It has not been clear whether the inhibition of one of the specific classes of TRPV1 stimuli enhances EM. Thus, we used JYL1421, which blocks TRPV1 activated solely by capsaicin. IG administration of JYL1421 at two doses did not change EM ( Fig. 3A and B). IP administration of JYL1421 also did not change EM ( Fig. 3C and D) . These results suggest that the administration of JYL1421 did not affect EM under normal conditions.
Intragastric co-administration of capsaicin and JYL1421 enhanced CHO more than the administration of capsaicin alone
The administration of JYL 1421, a selective antagonist of capsaicin activation of TRPV1, did not enhance EM (Fig. 3A-D) . We thought that this result was reasonable because there was no extrinsic capsaicin in the mouse body of the present experimental condition (Fig. 3A-D) . It has been reported that IG administration of capsaicin or capsinoids enhances EM by activating gastrointestinal TRPV1 (19) . Therefore, to examine whether the inhibition of TRPV1 activated by exogenous capsaicin affects EM, we intragastrically co-administered capsaicin and JYL1421. The co-administration of capsaicin and JYL1421 significantly enhanced CHO compared to administration of capsaicin alone (Fig. 3E) . These results suggest that the inhibition of TRPV1 activated by exogenous capsaicin enhanced CHO as well as AMG517 and AMG9810. different between the antagonist group and the vehicle group in any of the experiments (data not shown). Solutions were IG-or IP-administered through a gastric tube or needle, respectively, and the expired air was analyzed. The respiratory quotient, CHO, and fat oxidation were computed on the basis of VO 2 and CO 2 production. Respiratory quotient, which typically ranges between 0.7 and 1.0, is the ratio of carbon dioxide expired to oxygen consumed. High respiratory quotient values are indicative of low fat oxidation and high carbohydrate oxidation. Gas analysis was performed using an open circuit metabolic gas analysis system connected directly to a mass spectrometer (ARCO-2000; Arco System Inc., Chiba, Japan). Room air was pumped through the chambers at a rate of 0. 
(5).
Statistical analysis. The data are expressed as means + SE. Statistical analyses were done using an unpaired t-test. Statistics were calculated with the Microsoft Excel program (2011; WA), and differences with P-values < 0.05 were considered significant.
RESULTS

Administration of AMG517, a nonselective TRPV1 antagonist, increased VO 2 and CHO
IG administration of AMG517 significantly enhanced VO 2 and CHO (Fig. 1A, B) . These enhancements were dose-dependent. There was a significant difference between the AMG517-treated group and the vehicle-treated group in terms of the cumulative total VO 2 over 2 h, but not in CHO, at a 0.5 mg/kg dose (Fig. 1A) . At a 1.0 mg/kg dose, there were significant differences between the two groups in the cumulative total VO 2 and CHO over 2 h (Fig. 1B) .
We also checked the effect of the IP administration of AMG517 on changes in EM. IP administration of AMG517 increased VO 2 and CHO for 2 h at a 0.5 mg/kg dose (Fig. 1C) . At a 1.0 mg/kg dose, AMG517 significantly increased only VO 2 for 2 h (Fig. 1D) . These results suggest that both IG and IP administration of AMG517, a nonselective antagonist of TRPV1 that can inhibit all of the known types of stimuli, similarly enhanced EM. None of by TRPV1 antagonists. In addition, the EM enhancement patterns of AMG9810 differed depending on the route of administration (IG vs. IP). These results suggest that the specific nature of TRPV1 antagonists and the route of administration have different effects on EM. These findings are important to elucidate the physiological roles played by TRPV1. IG administration of AMG517 and AMG9810 enhanced EM in this study. These antagonists can inhibit all three activators of TRPV1. Naturally, some of the gastrointestinal TRPV1s in the stomach and colon are exposed to acids (11) . Thus, we conjectured that the inhibition of endogenous proton levels was a key to the EM increases induced by non-specific antagonists such as AMG517 and AMG9810. Furthermore, there are endogenous capsaicin analogs and TRPV1 agonists such as anandamide (arachidonoylethanolamide) and lipoxygenase products
DISCUSSION
In this study, we found that the administration of AMG517 and AMG9810, inhibitors of TRPV1 activated by heat, protons and capsaicin, enhanced EM in mice. However, the administration of JYL1421, which inhibits TRPV1 activated by capsaicin alone, did not change EM. Interestingly, the co-administration of capsaicin and JYL1421 increased CHO as well as AMG517 and AMG9810. These results suggest that the inhibition of TRPV1 enhances EM in mice when TRPV1 has been activated by [1] endogenous protons, [2] other endogenous TRPV1 agonists, [3] body temperature [after the decrease of the temperature threshold by endogenous TRPV1 modulators], and [4] exogenous capsaicin. Although hyperthermia is induced by the administration of TRPV1 antagonists (6), we found that EM is also changed ent study, blocking stimulators such as endogenous capsaicin analogs and heat (body temperature) by AMG517 and AMG9810 may have increased EM.
On the other hand, IP administration of AMG517 and AMG9810 also increased EM. These results suggest that the inhibition of TRPV1 proteins (other than gastrointestinal TRPV1) also increased EM. These results were reasonable because TRPV1 is widely expressed in peripheral sensory neurons innervating the skin, skeletal muscles, brain and other organs (25, 34, 39) . Because TRPV1 is expressed in those tissues, we were unable to determine the sites at which TRPV1 antagonists exerted their effects, although we did investigate 2 routes of administration, IG and IP. Further studies are needed to elucidate the target tissues of TRPV1 antagonist-induced EM increases observed in this study.
The most important result of the present study is (12-and 15-(S)-hydroperoxyeicosatetraenoic acids and 5-and 15-(S)-hydroxyeicosatetraenoic acids), N-oleoyldopamine and monoacylglycerols (2-arachidonoylglycerol and 1-arachidonoylglycerol) in the body (3, 13, 43, 44) . Moreover, it is well known that TRPV1 can be activated synergistically by ligands (4, 37) . For examples, protons and capsaicin enhance TRPV1 activation by heat. Extracellular ATP potentiates TRPV1 currents induced by capsaicin or protons through metabotropic P2Y 1 receptor activation in a protein kinase C-dependent pathway (38) . Note that the temperature threshold of TRPV1 (43°C) is shifted to 35°C after phosphorylation by protein kinase C. Thus, in the presence of ATP, body temperature can activate TRPV1 after phosphorylation. Bradykinin has also been reported to reduce the temperature threshold of TRPV1 through a protein kinase C-dependent pathway (33) . Thus, in the pres- TRPV1s are activated by protons, other endogenous TRPV1 modulators and body temperature under non-pathophysiological states, we hypothesized that the inhibition of stimulators by an antagonist would increase EM. Furthermore, as observed in this study, it is likely that the activation of TRPV1 by an extrinsic agonist such as capsaicin and the subsequent inhibition of TRPV1 by an antagonist would increase EM. The reason why TRPV1 agonists have that the co-administration of capsaicin and JYL1421 rather than administration of capsaicin alone enhanced CHO (Fig. 3E) . Over the past 30 years, it has been reported that the intake of plant-derived TRPV1 agonists such as capsaicin and capsinoids increased EM in experimental animals and humans (26, 41) . Thus, our present results and the earlier studies show that both extrinsic antagonists and agonists have the ability to enhance EM. Since some been explored as anti-pain drugs is that TRPV1 is desensitized after the TRPV1 agonists-induced activation (15). Thus, it is possible that desensitization may be partly involved in EM enhancement by TRPV1 agonists and further studies will be needed to examine this possibility. This study showed that the administration of TRPV1 antagonists enhanced EM. However, there is the possibility that the enhancement of EM by TRPV1 antagonists was not induced via TRPV1. To explore that possibility, experiments using TRPV1 KO mice are needed in the future. Previously, Gavva et al. indicated that the administration of AMG517 did not cause hyperthermia in TRPV1 KO mice (7). Furthermore, Alawi et al. revealed that AMG9810 did not induce hyperthermia in TRPV1 KO mice (1) . Thus, it is quite possible that TRPV1 antagonists enhanced EM via TRPV1 in this study because the increase of body temperature by capsaicin administration was linked with the VO 2 increase as shown by Kobayashi et al. (22) . It is apparent that studies using TRPV1 KO mice and JYL1421 are also needed.
In summary, the present study suggests that the inhibition of TRPV1 activated by protons, endogenous TRPV1 modulators (capsaicin analogs), body temperature and exogenous capsaicin increases EM in mice. The type of TRPV1 antagonists and route of their administration have different effects on EM in a normal body. These findings help reveal the roles played by TRPV1 and should promote the development of new drugs and supplements for regulating EM.
